Known targets — ChEMBL curated mechanism
rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Minocycline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 9/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.70 |
| ▸ | USP2 | O75604 | 4/20 | 0.70 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.70 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.70 |
| ▸ | GRK6 | P43250 | 1/20 | 0.70 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.70 |
| ▸ | ALB | P02768 | 1/20 | 0.70 |
| ▸ | MAPT | P10636 | 6/20 | 0.69 |
| ▸ | HPGD | P15428 | 2/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.69 |
| ▸ | RECQL | P46063 | 2/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.61 |
| ▸ | THPO | P40225 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.60 |
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | BLM | P54132 | 1/20 | 0.60 |
| ▸ | NR1I2 | O75469 | 3/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Minocycline SCHEMBL9340562 | 1.00 | TDP1 (0.70) | TDP1KDM4EUSP2HIF1APTGS1 | |
| Minocycline SCHEMBL13520108 | 1.00 | TDP1 (0.70) | TDP1KDM4EUSP2HIF1APTGS1 | |
| Minocycline SCHEMBL1820770 | 1.00 | TDP1 (0.70) | TDP1KDM4EUSP2HIF1APTGS1 | |
| Minocycline SCHEMBL13520109 | 1.00 | TDP1 (0.70) | TDP1KDM4EUSP2HIF1APTGS1 | |
| Minocycline SCHEMBL12532767 | 1.00 | TDP1 (0.70) | TDP1KDM4EUSP2HIF1APTGS1 | |
| Minocycline SCHEMBL13520116 | 1.00 | TDP1 (0.70) | TDP1KDM4EUSP2HIF1APTGS1 | |
| Minocycline SCHEMBL22171064 | 1.00 | TDP1 (0.70) | TDP1KDM4EUSP2HIF1APTGS1 | |
| Minocycline SCHEMBL20716523 | 1.00 | TDP1 (0.70) | TDP1KDM4EUSP2HIF1APTGS1 | |
| Minocycline SCHEMBL21931671 | 1.00 | TDP1 (0.70) | TDP1KDM4EUSP2HIF1APTGS1 | |
| Minocycline SCHEMBL11911315 | 1.00 | TDP1 (0.70) | TDP1KDM4EUSP2HIF1APTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238315-A1 | MINOCYCLINE COMPOUNDS FOR BIODEFENSE | PARATEK PHARM INNC (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240238315-A1 | MINOCYCLINE COMPOUNDS FOR BIODEFENSE | PARATEK PHARM INNC (US) | 2024-07-18 | — | — | US | disclosed |
| US-20210395189-A1 | SUBSTITUTED TETRACYCLINE COMPOUNDS | PARATEK PHARMACEUTICALS, INC. | 2021-12-23 | — | — | US | disclosed |
| US-11129839-B2 | Minocycline compounds for biodefense | PARATEK PHARMACEUTICALS, INC. (US) | 2021-09-28 | — | — | US | disclosed |
| US-20200330489-A1 | MINOCYCLINE COMPOUNDS FOR BIODEFENSE | PARATEK PHARMACEUTICALS, INC. | 2020-10-22 | — | — | US | disclosed |
| WO-2020135508-A1 | MINOCYCLINE(II) P-CHLOROBENZENE SULFONATE CRYSTAL FORM, PREPARATION METHOD THEREFOR AND USE THEREOF | 浙江昌海制药有限公司 | 2020-07-02 | — | — | WO | disclosed |
| US-10252984-B2 | Inhibiting G protein coupled receptor 6 kinase polypeptides | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2019-04-09 | — | — | US | disclosed |
| US-20180133231-A1 | MINOCYCLINE COMPOUNDS FOR BIODEFENSE | PARATEK PHARMACEUTICALS, INC. | 2018-05-17 | — | — | US | disclosed |
| US-20180133231-A1 | MINOCYCLINE COMPOUNDS FOR BIODEFENSE | PARATEK PHARMACEUTICALS, INC. | 2018-05-17 | — | — | US | disclosed |
| US-20180104262-A1 | SALTS AND POLYMORPHS OF A TETRACYCLINE COMPOUND | PARATEK PHARMACEUTICALS, INC. | 2018-04-19 | — | — | US | disclosed |
| US-20080287401-A1 | Methods for Synthesizing and Purifying Aminoalkyl Tetracycline Compounds | PARATEK PHARMACEUTICALS, INC. | 2008-11-20 | — | — | US | disclosed |
| WO-2008079339-A2 | TETRACYCLINE DERIVATIVES FOR THE TREATMENT OF BACTERIAL, VIRAL AND PARASITIC INFECTIONS | PARATEK PHARMACEUTICALS, INC. (US) | 2008-07-03 | — | — | WO | disclosed |
| EP-1890997-A1 | METHODS OF PURIFYING TIGECYCLINE | Wyeth a Corporation of the State of Delaware (US) | 2008-02-27 | — | — | EP | disclosed |
| WO-2008020827-A2 | ALTERED POLYPEPTIDES, IMMUNOCONJUGATES THEREOF, AND METHODS RELATED THERETO | BIOGEN IDEC MA INC. (US) | 2008-02-21 | — | — | WO | disclosed |
| US-20070248988-A1 | Binding molecules and methods of use thereof | BIOGEN MA INC. | 2007-10-25 | — | — | US | disclosed |
| US-20070248988-A1 | Binding molecules and methods of use thereof | BIOGEN MA INC. | 2007-10-25 | — | — | US | disclosed |
| US-20070093455-A1 | 10-substituted tetracyclines and methods of use thereof | PARATEK PHARMACEUTICALS, INC. | 2007-04-26 | — | — | US | disclosed |
| US-20070093455-A1 | 10-substituted tetracyclines and methods of use thereof | PARATEK PHARMACEUTICALS, INC. | 2007-04-26 | — | — | US | disclosed |
| WO-2006130431-A1 | METHODS OF PURIFYING TIGECYCLINE | WYETH (US) | 2006-12-07 | — | — | WO | disclosed |
| US-6617318-B1 | 7-substitted tetracyclines are effective against tetracycline-resistant E. coli, S. aureus and E. faecalis strains | TRUSTEES OF TUFTS COLLEGE | 2003-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093455-A1 | 10-substituted tetracyclines and methods of use thereof | TET3, TET1, TMSB10 | TDP1 1397/4885KDM4E 996/4885USP2 2844/4885 |
| US-11129839-B2 | Minocycline compounds for biodefense | CD68, CD14, TREH | TDP1 2875/4885KDM4E 3775/4885USP2 2225/4885 |
| US-20180104262-A1 | SALTS AND POLYMORPHS OF A TETRACYCLINE COMPOUND | TPR, MALT1, TBCA | TDP1 1583/4885KDM4E 4413/4885USP2 4310/4885 |
| US-20070248988-A1 | Binding molecules and methods of use thereof | SHBG, CACYBP, CD2BP2 | TDP1 1801/4885KDM4E 4410/4885USP2 3510/4885 |
| US-20200330489-A1 | MINOCYCLINE COMPOUNDS FOR BIODEFENSE | CD68, CD14, TREH | TDP1 2875/4885KDM4E 3775/4885USP2 2225/4885 |
| US-20080287401-A1 | Methods for Synthesizing and Purifying Aminoalkyl Tetracycline Compounds | NPEPPS, AAAS, AADAC | TDP1 1642/4885KDM4E 587/4885USP2 1688/4885 |
| US-20210395189-A1 | SUBSTITUTED TETRACYCLINE COMPOUNDS | TET1, TET3, MYC | TDP1 2522/4885KDM4E 1193/4885USP2 2300/4885 |
| US-20240238315-A1 | MINOCYCLINE COMPOUNDS FOR BIODEFENSE | CD68, CD14, TREH | TDP1 2875/4885KDM4E 3775/4885USP2 2225/4885 |
| US-20180133231-A1 | MINOCYCLINE COMPOUNDS FOR BIODEFENSE | CD68, CD14, TREH | TDP1 2875/4885KDM4E 3775/4885USP2 2225/4885 |
| US-10252984-B2 | Inhibiting G protein coupled receptor 6 kinase polypeptides | GRK6, GRK2, GRK3 | TDP1 3105/4885KDM4E 4504/4885USP2 2725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.